BRPI0512393A - vacinação de jaritataca e/ou mangusto contra raiva - Google Patents

vacinação de jaritataca e/ou mangusto contra raiva

Info

Publication number
BRPI0512393A
BRPI0512393A BRPI0512393-3A BRPI0512393A BRPI0512393A BR PI0512393 A BRPI0512393 A BR PI0512393A BR PI0512393 A BRPI0512393 A BR PI0512393A BR PI0512393 A BRPI0512393 A BR PI0512393A
Authority
BR
Brazil
Prior art keywords
rabies
mongoose
skunk
vaccination against
against rabies
Prior art date
Application number
BRPI0512393-3A
Other languages
English (en)
Inventor
Joanne L Maki
Original Assignee
Merial Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merial Ltd filed Critical Merial Ltd
Publication of BRPI0512393A publication Critical patent/BRPI0512393A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/205—Rhabdoviridae, e.g. rabies virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24145—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20111—Lyssavirus, e.g. rabies virus
    • C12N2760/20134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6072—Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses
    • C12N2810/6081—Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses rhabdoviridae, e.g. VSV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

VACINAçãO DE JARITATACA E/OU MANGUSTO CONTRA RAIVA. A presente invenção refere-se às vacinas anti-rábicas recombinantes e à administração oral de tais vacinas às jaritatacas e/ou mangustos. Vantajosamente, a vacina anti-rábica pode compreender um vírus da vacínia recombinante contendo um gene de glicoproteína da raiva. A invenção abrange métodos de vacinar jaritatacas e/ou mangustos pela administração de uma vacina anti-rábica que pode compreender um vírus da vacínia recombinante contendo um gene de glicoproteína da raiva.
BRPI0512393-3A 2004-06-21 2005-06-20 vacinação de jaritataca e/ou mangusto contra raiva BRPI0512393A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US58169804P 2004-06-21 2004-06-21
US62787804P 2004-11-15 2004-11-15
PCT/US2005/021918 WO2006002160A1 (en) 2004-06-21 2005-06-20 Vaccination of skunks and/or mongooses against rabies

Publications (1)

Publication Number Publication Date
BRPI0512393A true BRPI0512393A (pt) 2008-03-11

Family

ID=35782124

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0512393-3A BRPI0512393A (pt) 2004-06-21 2005-06-20 vacinação de jaritataca e/ou mangusto contra raiva

Country Status (6)

Country Link
US (1) US20050282210A1 (pt)
EP (1) EP1778281A4 (pt)
BR (1) BRPI0512393A (pt)
CA (1) CA2571316A1 (pt)
MX (1) MXPA06015263A (pt)
WO (1) WO2006002160A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2951660T3 (es) 2006-12-27 2023-10-24 Zoetis Services Llc Procedimientos de administración de vacunas
TW200907058A (en) * 2007-05-30 2009-02-16 Wyeth Corp Raccoon poxvirus expressing rabies glycoproteins
US9216213B2 (en) 2011-04-20 2015-12-22 Merial, Inc. Adjuvanted rabies vaccine with improved viscosity profile
WO2013138776A1 (en) 2012-03-16 2013-09-19 Merial Limited Novel methods for providing long-term protective immunity against rabies in animals, based upon administration of replication-deficient flavivirus expressing rabies g
AU2015343369B2 (en) 2014-11-03 2018-11-22 Georgia Tech Research Corporation Methods of using microneedle vaccine formulations to elicit in animals protective immunity against rabies virus

Also Published As

Publication number Publication date
CA2571316A1 (en) 2006-01-05
WO2006002160A1 (en) 2006-01-05
EP1778281A1 (en) 2007-05-02
US20050282210A1 (en) 2005-12-22
MXPA06015263A (es) 2007-09-27
EP1778281A4 (en) 2010-01-20

Similar Documents

Publication Publication Date Title
MX2023000411A (es) Vacuna combinada de sars-cov-2 e influenza.
ES2488941T3 (es) Vectores y constructos de liberación de antígenos de virus de la gripe
NO20054608L (no) Influensavirusvaksine
EA200970013A1 (ru) Вакцинация против гриппа по схеме многократного введения с использованием безадъювантной дозы
DE60239594D1 (de) Influenza vakzinzusammensetzungen zur intradermaler verabreichung
MX342639B (es) Virus de la influenza recombinantes de alta titulacion para vacunas y terapia genica.
MX2019003682A (es) Antigenos de consenso del virus sincitial respiratorio humano, constructos de acido nucleico y vacunas hechas de estos, y metodos para utilizarlas.
DK1881845T3 (da) Nipah-virusvacciner
WO2009026465A3 (en) Composition and methods of making and using influenza proteins
EA201171032A1 (ru) Схемы лечения с помощью вакцины против гриппа, связанного с пандемическими штаммами
CO2019000214A2 (es) Vacuna contra virus de bronquitis infecciosa
JP2013523096A (ja) インフルエンザマトリックス２タンパク質の外部ドメイン、発現システムおよびそれらの使用
CY1120015T1 (el) Μεθοδοι χορηγησης εμβολιων
WO2005081716A3 (en) DNA VACCINES TARGETING ANTIGENS OF THE SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS (SARS-CoV)
AU2014232363A8 (en) Foot and mouth disease virus (FMDV) consensus proteins, coding sequences therefor and vaccines made therefrom
SA522441314B1 (ar) لقاحات لوُرام حليمي تنفسي متكرر وطرق استخدامها
WO2003078640A3 (en) Recombinant drug-sensitive vaccinia virus as smallpox vaccine
WO2008060385A3 (en) Li-key enhanced vaccine potency
BR112018072719A2 (pt) molécula de ácido nucleico isolada, composição, e, métodos de indução de uma resposta imune contra o filovírus e o ebolavirus, de tratamento de um indivíduo que foi diagnosticado com ebolavirus e de prevenção da infecção por ebolavirus
WO2006062637A3 (en) Influenza vaccination
EA201990670A1 (ru) ВАКЦИНЫ НА ОСНОВЕ мРНК В ЛИПИДНЫХ НАНОЧАСТИЦАХ
EA201070014A1 (ru) Внутрикожная вакцина против гриппа
WO2009014382A3 (en) Cxcl11 adjuvant compositions and uses thereof
JP2013511552A5 (pt)
WO2006101810A3 (en) Theileria parva dna vaccines

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired